004 Waiting Time (months) 28.7 (0–86) 7 (0–63) 0.05 Time between US tests (months) 12.4 (0–37) 9 (0–74) < 0.0001 US tests/patients (N) 2 (0–5) 2 (0–6) 0.19 Out of 546 patients, Group A comprised 290 individuals (53.1%) (melanoma thickness > 1 mm),

and Group B comprised 256 individuals (46.9%) (melanoma thickness < 1 mm) (Figure 1). Figure 1 Inappropriated test according to tumor localization Alvespimycin mw for patients of Group A and Group B. In Group A, the median age was 58 years, while in Group B it was 52 years. Waiting time for Group A patients was 7 days on average, with a range of 0–63 days, whereas for Group B, average waiting time was 28.7 days, with a range of 0–86 days. In the case of repeated tests, the interval between each test for Group A patients was 12.4 months on average , with a range of 0–37 months, whereas 9.3 months, with a range of 0–74 months was reported for Group B. As for costs and test appropriateness: a total of 644 tests were performed in Group A (290 patients). In this group, 104 patients were found to have an inappropriate motivation (35.9%), for a total of 206 unjustified examinations (32%). Consequently, for this group there was a cost of 6,709 Euros for unjustified tests out of a total of 21,902 Euros. 4SC-202 596 tests were performed in Group B, formed of 256 individuals. In this group, 92 patients with

at least one unjustified request (35.9%), and a total of 172 unjustified tests (29%) were reported. Consequently,

5,704 Inositol monophosphatase 1 Euros was spent for unjustified tests out of a total cost of 19,976 Euros. It is interesting to note that the percentage of unjustified tests is similar in the two groups (32% for Group A vs. 29% for Group B, p = 0.53), although for different reasons. In fact, the most common among the unjustified requests in Group A was a test prescribed after more than 5 years (62.5%), whereas in Group B there were two main causes, the excessively long follow-up (35.6%) and incorrect indication of the lymph node station (37.8) (Figure 2). Figure 2 Reasons for Inappropriateness for patient both Group A and Group B. Moreover, on the basis of patients’ perception, test usefulness was deemed very high since 97% of them expressed a satisfaction rate equivalent to the maximum VAS score. In a subgroup of melanoma in situ (N = 81 patients, 13.5%), identified as part of Group B, further thorough exams were requested for 11 patients because of the incidental discovery of seven large hepatic angiomas, two adrenal adenomas, a complex renal cyst and a pancreatic pseudocyst, all irrelevant in relation to evolution of the Lazertinib datasheet clinical outcome as well as expensive for the national healthcare system and stressful for the patients. We found less percentages of “incidentalomas” in the other Subgroup B (5%) and Group A (12%).